)
Visual
earnings real time
Sun Pharmaceutical Industries
Sun Pharmaceutical Industries (SUNPHARMA) investor relations material
Sun Pharmaceutical Industries Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 25/26 earnings summary31 Jan, 2026
Executive summary
Q3 FY2026 sales reached INR 154,691 million, up 15.1% year-over-year, with milestone income of $55 million in Rest of World markets; ex-milestone, sales growth was 14.7%.
Gross margin improved to 81% due to a better product mix; EBITDA rose 23.4% to INR 49,485 million, with margins at 31.9%.
Reported net profit after tax was INR 33,688 million, up 16% year-over-year; adjusted net profit was INR 35,367 million, up 9.9%.
Interim dividend of INR 11 per share declared for FY2026, with record date set for February 5, 2026.
Financial highlights
Nine-month FY2026 sales were INR 436,604 million, up 11.3% year-over-year; gross margin at 80%.
EBITDA for nine months was INR 137,772 million, up 19.2%, with a margin of 31.4%.
Adjusted net profit for nine months was INR 96,508 million, up 6.1%.
Net cash position at $3.2 billion consolidated.
R&D investment for Q3 FY2026 was INR 8,928 million (5.8% of sales); 9M FY2026: INR 25,783 million (5.9% of sales).
Outlook and guidance
Management highlighted well-rounded growth across all businesses, led by Branded businesses in India, Emerging Markets, and Global Innovative Medicines.
Continued expansion of innovative product offerings, including new launches in the US and India.
India semaglutide launch strategy details
U.S. generics recovery timeline and drivers
M&A strategy for future growth and targets
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- DCRU
Strong FY2025 growth, high occupancy, and strategic expansion driven by digital demand. - WOSG
Q3 sales growth exceeded expectations, guidance raised, and US presence expanded. - NOBA
Record profit growth, robust capital, and SME expansion drive strong 2025 results. - SF
Margins expanded to 27% despite revenue decline and large non-cash impairments. - IFX
Q1 FY26 revenue up 7% YoY to €3.66bn, led by AI and automotive, with key acquisition and investments. - WRT1V
All-time high profit and cash flow, with robust Marine and Energy growth and major investments. - CB
Record net income and strong underwriting drive robust growth, with positive 2026 outlook. - BERG
EBITA and margins rose 12% with 4% organic growth, supported by acquisitions and efficiency. - APOTEA
Full-year revenue up 10.1%, but Q4 margin dropped to 1.3% on higher costs. - V2RETAIL
Q3 and 9M FY26 saw strong revenue and profit growth, aided by expansion and lease gains.
Next Sun Pharmaceutical Industries earnings date
Q4 25/2622 May, 2026
Sun Pharmaceutical Industries
Next Sun Pharmaceutical Industries earnings date
Q4 25/2622 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Sun Pharmaceutical Industries Limited operates as a pharmaceutical company. It manufactures, develops and markets generic pharmaceutical products, active pharmaceutical ingredients and intermediates, and formulation products for various dosage forms.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage